We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-8.12%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$116M
AUM Growth
-$19.4M
Cap. Flow
-$5.91M
Cap. Flow %
-5.09%
Top 10 Hldgs %
74.92%
Holding
39
New
9
Increased
9
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$6.7M
2
CMRX
Chimerix, Inc.
CMRX
+$5.04M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.69M
4
INSY
Insys Therapeutics, Inc.
INSY
+$2.77M
5
MZOR
Mazor Robotics Ltd.
MZOR
+$2.13M

Top Sells

Rank Stock Value
1
OMER icon
Omeros
OMER
+$6.04M
2
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$4.49M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$4.12M
4
LAB icon
Standard BioTools
LAB
+$3.97M
5
EPZM
Epizyme, Inc
EPZM
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 83.33%
2 Miscellaneous 16.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
$17.3M 14.94%
790,000
+254,000
+47% +$5.04M
TVTX icon
2
Travere Therapeutics
TVTX
$6.36B
$14.3M 12.31%
1,216,400
+63,170
+5% +$856K
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$10.6M 9.12%
1,660,000
-10,000
-0.6% -$68.8K
PCYC
4
DELISTED
PHARMACYCLICS INC
PCYC
$8.97M 7.73%
100,000
-15,000
-13% -$1.41M
GNMK
5
DELISTED
GenMark Diagnostics, Inc
GNMK
$6.76M 5.83%
500,000
+65,000
+15% +$678K
BIND
6
DELISTED
BIND THERAPEUTICS INC
BIND
$6.49M 5.59%
492,000
+65,000
+15% +$636K
NSPR icon
7
InspireMD
NSPR
$41.6M
– –
0
– –
CEMP
8
DELISTED
Cempra, Inc.
CEMP
$5.42M 4.67%
504,800
+24,800
+5% +$239K
CLVS
9
DELISTED
Clovis Oncology, Inc.
CLVS
$5.37M 4.63%
+130,000
New +$6.7M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2.05B
$5.27M 4.54%
+115,000
New +$4.69M
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
$4.21M 3.63%
135,000
– –
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$3.49M 3.01%
1,378,584
– –
INSY
13
DELISTED
Insys Therapeutics, Inc.
INSY
$2.68M 2.31%
+171,600
New +$2.77M
TTPH
14
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.29M 1.97%
8,485
+485
+6% +$104K
MZOR
15
DELISTED
Mazor Robotics Ltd.
MZOR
$2.11M 1.82%
+120,000
New +$2.13M
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.59B
$2.02M 1.74%
+45,000
New +$1.85M
EVOK
17
DELISTED
Evoke Pharma
EVOK
$1.96M 1.69%
1,684
+63
+4% +$72.4K
SCTL
18
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.76M 1.52%
+245,300
New +$1.49M
CELGZ
19
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$1.72M 1.48%
660,000
– –
KPTI icon
20
Karyopharm Therapeutics
KPTI
$44M
$1.4M 1.2%
+2,000
New +$931K
BLRX
21
BioLineRX
BLRX
$12.1M
$1.35M 1.17%
1,083
-1,335
-55% -$1.67M
CDXS icon
22
Codexis
CDXS
$182M
$1.2M 1.03%
820,000
+121,700
+17% +$193K
CPXX
23
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$1.07M 0.93%
338,402
+13,402
+4% +$36.9K
KBIO
24
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$730K 0.63%
40,000
-28,125
-41% -$481K
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$31.7B
$455K 0.39%
+7,200
New +$428K
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2014 Portfolio in Review

As of Q2 2014, Opaleye Management held 39 positions worth $116M, down 14% from $135M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Opaleye Management withdrew a net $5.91M in Q2 2014, closing 11 positions and reducing 5 holdings. Its most notable exit was Omeros, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 80% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Clovis Oncology, Inc. worth $5.37M.

  • Opaleye Management's largest Q2 2014 buy was Clovis Oncology, Inc.: 130,000 shares worth $5.37M.
  • Opaleye Management added most to Chimerix, Inc. in Q2 2014, an estimated $5.04M increase.
  • Opaleye Management's biggest Q2 2014 reduction was BioLineRX, cutting an estimated $1.67M.
  • Opaleye Management fully exited Omeros in Q2 2014, selling an estimated $6.04M.
  • Opaleye Management's ten largest holdings make up 75% of its $116M portfolio in Q2 2014.
  • Opaleye Management opened 9 new positions and closed 11 in Q2 2014.
  • Opaleye Management's portfolio value fell 14% quarter-over-quarter to $116M.

Based on Opaleye Management's 13F filing for Q2 2014, filed 14 Aug 2014.